Latest News

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performanc...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Rev...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results De...

Teva Statement on European Commission Decision; Company to Appeal

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Cand...

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide...

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on Nove...

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debili...

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TE...

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schi...

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All...

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inf...

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody ...

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on Jul...

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Co...

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the Uni...

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended...

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a...

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘...

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentra...

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stela...

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness an...

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Re...

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May ...

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia ...

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development o...

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first inte...

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘5...

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2...